Latest Asx News

American West Metals has commenced a 5,000-metre diamond drilling campaign at its West Desert Project in Utah, targeting high-grade indium, gallium, and copper to bolster US critical metals security.

Ardiden Limited’s initial drill results at the Astoria deposit confirm a robust high-grade gold system, underpinning the potential for significant resource expansion along its Rouyn Gold Project corridor in Québec.

88 Energy has raised A$5 million through a heavily oversubscribed placement to advance pre-drilling activities for its high-potential Augusta-1 well in Alaska, targeting significant oil resources in the North Slope.

Marvel Gold has identified promising new mineralisation corridors at its Hanang Gold Project in Tanzania following an extensive drone magnetic survey, setting the stage for a maiden drilling campaign starting in April.

RLF AgTech has raised $4.5 million through an institutional placement to accelerate its commercial rollout and meet rising demand amid global fertiliser shortages.

HyTerra Limited has partnered with Omani operator ARA Natural Resources to explore geologic hydrogen opportunities in Oman’s Semail Ophiolite, aiming to pioneer commercialisation in a promising low-carbon energy frontier.

Weebit Nano has successfully raised A$87 million through institutional and Israeli placements, positioning itself to fast-track its advanced ReRAM technology development. The capital raise includes a forthcoming share purchase plan for retail investors.

Firebrick Pharma has secured its first regulatory approval for Nasodine Nasal Spray in Indonesia, paving the way for entry into Southeast Asia’s largest market. This milestone marks a significant step in the company’s international expansion strategy.

MyEco Group launches a $2 million Series 2 convertible note offer targeting sophisticated investors, featuring a 10.5% annual interest and a 15% discount on share conversion prices.

InFocus Group Holdings has completed Codexa, a proprietary sweepstakes casino platform targeting the booming US market, with plans for licensing and potential sale.

Titomic Limited has secured a significant $1.7 million purchase order from the Netherlands’ Royal NLR, reinforcing its foothold in European aerospace and defense additive manufacturing.

Radiopharm Theranostics has initiated dosing in its Phase 1 clinical trial of RAD 402, a novel radiolabelled antibody targeting KLK3 in advanced prostate cancer. Early data from the trial’s initial dose levels are expected in the second half of 2026.